Altimmune heads into the post-earnings period with nearly half its float sold short and a lending market that has loosened sharply — a combination that makes the stock one of the more structurally charged setups in small-cap biotech right now.
Short interest is the dominant story here. Nearly 49% of the free float is sold short — a level that has held remarkably stable for six weeks, oscillating in a tight band between 47% and 51% without any meaningful cover. The FINRA fortnightly count put official short shares at 51.9 million as of July 31, with days to cover running at 11.45 — meaning even a modest uptick in buying pressure would take bears more than two weeks to unwind. The ORTEX short score of 81.5 ranks ALT in the 3rd percentile on short score rank, placing it among the most heavily shorted names in the entire universe. What makes this week's reading notable is the direction: short shares jumped 3% on August 11 alone, the sharpest single-day build in recent history, pushing the monthly net change to +6.4%.
The borrow picture tells a different story from the lending pressure bears might expect. Availability has loosened dramatically — from a tight 55% reading on August 4, it widened to 73% by August 11, up 32% on the week. That compares with a 52-week trough of just 24%. At 73%, the lending pool still holds roughly three shares available for every four already borrowed, which is not particularly tight by historical standards. Cost to borrow remains negligible at 0.50%, up modestly from a month ago but nowhere near levels that would impose meaningful carry pain on short sellers. Options positioning is lightly elevated — the put/call ratio at 0.078 is slightly above its 20-day average of 0.067, roughly 1.2 standard deviations above the mean — but far from the hedging extremes seen earlier this year when the ratio briefly reached 0.35. The overall positioning picture is one of entrenched bearishness in short books, but no acute squeeze pressure in the funding market.
Against this backdrop, the Street remains broadly constructive but has been trimming its sails. Leerink Partners initiated coverage in late June with an Outperform and a $10 target. Earlier in May, HC Wainwright cut its target from $25 to $20 while keeping Buy, and Citizens shaved its target from $14 to $11 at Market Outperform. The consensus mean target of $17.22 implies enormous theoretical upside from the current $3 handle — but that gap reflects the binary nature of the asset rather than a near-term call. Bears point to regulatory uncertainty in MASH (no drugs yet approved in the space), the risk of dilution as Phase 3 costs mount, and Q4 2025 EPS that came in below expectations. Bulls counter with roughly $340 million in pro-forma cash, pemvidutide's dual-action mechanism and favorable tolerability data, and a breakthrough therapy designation that accelerates FDA dialogue. Factor scores are consistent with the bear lean: the dividend score is 32, EPS surprise ranks at the 30th percentile, and days-to-cover ranks in the bottom 6th percentile of the universe.
The institutional ownership structure is worth noting. BlackRock added 7.6 million shares, raising its stake to 10.5% of shares as of July 31 — a meaningful passive accumulation. State Street also added nearly 5 million shares in the same period. Those are index-linked flows rather than active conviction bets, but they matter given the float constraints. Meanwhile, specialist healthcare funds Deep Track Capital (10% of shares) and TCG Crossover Management (5.1%) built substantial new positions as of late April, suggesting dedicated biotech money remains in the name. The CEO bought 15,000 shares at $3.14 in early April and another 20,000 at $3.54 in March — though those trades are now over four months old and the stock has drifted below those entry points.
The peer cohort tells a quiet story of relative weakness. While SANA gained 11.5% on the week and ABEO added 8.5%, ALT slipped 2.3% — underperforming virtually every correlated name in the basket. Earnings just crossed the tape on August 12, so the next focal point shifts to any data readout from the alcohol use disorder Phase 2 program and management's updated commentary on Phase 3 MASH enrollment pace.
See the live data behind this article on ORTEX.
Open ALT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
